About Keros Therapeutics, Inc.
https://www.kerostx.comKeros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need.
CEO
Jasbir S. Seehra
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 102
Ratings Snapshot
Rating : A
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Truist Securities
Buy
Oppenheimer
Outperform
Scotiabank
Sector Outperform
Wells Fargo
Overweight
Piper Sandler
Overweight
Grade Summary
Showing Top 6 of 10
Price Target
Institutional Ownership
ADAR1 CAPITAL MANAGEMENT, LLC
Shares:5.39M
Value:$105.25M
VANGUARD GROUP INC
Shares:2.72M
Value:$53.1M
BLACKROCK, INC.
Shares:2.72M
Value:$53.07M
Summary
Showing Top 3 of 170
About Keros Therapeutics, Inc.
https://www.kerostx.comKeros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $14.26M ▼ | $29.25M ▼ | $-7.28M ▲ | -51.04% ▲ | $-0.18 ▲ | $-8.31M ▲ |
| Q2-2025 | $18.17M ▼ | $57.62M ▼ | $-30.7M ▼ | -168.96% ▼ | $-0.76 ▼ | $-32.55M ▼ |
| Q1-2025 | $211.25M ▲ | $59.21M ▲ | $148.45M ▲ | 70.27% ▲ | $3.66 ▲ | $152.38M ▲ |
| Q4-2024 | $3.04M ▲ | $55.96M ▼ | $-46.03M ▲ | -1.51K% ▲ | $-1.14 ▲ | $-29.14M ▲ |
| Q3-2024 | $388K | $58.73M | $-52.96M | -13.65K% | $-1.47 | $-58.34M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $693.47M ▲ | $742.78M ▼ | $39.2M ▼ | $703.58M ▼ |
| Q2-2025 | $690.22M ▼ | $757.16M ▼ | $50.43M ▼ | $706.73M ▼ |
| Q1-2025 | $720.54M ▲ | $784.56M ▲ | $55.69M ▲ | $728.87M ▲ |
| Q4-2024 | $559.93M ▲ | $615.89M ▲ | $44.33M ▼ | $571.55M ▲ |
| Q3-2024 | $530.68M | $579.27M | $46.44M | $532.84M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-7.28M ▲ | $3.25M ▲ | $-132K ▲ | $140K ▲ | $3.26M ▲ | $3.12M ▲ |
| Q2-2025 | $-30.7M ▼ | $-29.62M ▼ | $-720K ▼ | $17K ▲ | $-30.33M ▼ | $-30.34M ▼ |
| Q1-2025 | $148.45M ▲ | $161.17M ▲ | $-565K ▼ | $4K ▼ | $160.61M ▲ | $160.61M ▲ |
| Q4-2024 | $-46.03M ▲ | $-46.01M ▼ | $-289K ▲ | $75.54M ▼ | $29.25M ▼ | $-46.3M ▼ |
| Q3-2024 | $-52.96M | $-30.5M | $-386K | $155.94M | $125.06M | $-30.89M |
Revenue by Products
| Product | Q4-2024 | Q2-2025 | Q1-2025 | Q3-2025 |
|---|---|---|---|---|
 License | $0 ▲ | $0 ▲ | $200.00M ▲ | $10.00M ▼ |
 Service Other | $0 ▲ | $20.00M ▲ | $20.00M ▲ | $0 ▼ |
 Service | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Jasbir S. Seehra
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 102
Ratings Snapshot
Rating : A
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Truist Securities
Buy
Oppenheimer
Outperform
Scotiabank
Sector Outperform
Wells Fargo
Overweight
Piper Sandler
Overweight
Grade Summary
Showing Top 6 of 10
Price Target
Institutional Ownership
ADAR1 CAPITAL MANAGEMENT, LLC
Shares:5.39M
Value:$105.25M
VANGUARD GROUP INC
Shares:2.72M
Value:$53.1M
BLACKROCK, INC.
Shares:2.72M
Value:$53.07M
Summary
Showing Top 3 of 170